![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
The development of inhibitors and medicines for collagenase-3 (MMP-13) as a therapeutic target for the treatment of some diseases such as cancer and arthritis has attracted much interest. A key technology for screening inhibitors and medicines is to obtain the activated recombinant catalytic domain of collagenase-3 (cdMMP-13). In this study, for the first time, a chromatographic method was used to refold the Histidine-tagged (His-tagged) cdMMP-13 (His-cdMMP-13). After the optimization of gradient elution modes and chromatographic conditions, the recovery yield of His-cdMMP-13 reached ∼83% with a relative activity of ∼92%. Both the recovery yield and relative activity of the His-cdMMP-13 were higher than those obtained by dialysis. Finally, to prevent the slight autoproteolytic degradation in the desalting step, different small molecule inhibitors were separately added into the desalting buffer, and the results of circular dichroism (CD) spectral analysis indicate that the addition of inhibitors did not affect the secondary structure of the target protein. The His-cdMMP-13, refolded through chromatography with a good activity, may be used to screen inhibitors and medicines.
Acknowledgments
The authors are grateful to Xuexun Fang for providing the E. coli strain BL21 to express the His-tagged MMP-13 catalytic domain.
Notes
a Relative activity = activity of target protein/activity of commercial reference × 100%.